ABBV vs EXEL
AbbVie vs Exelixis — AI-powered side-by-side comparison
| Metric | ABBV | EXEL |
|---|
| AI Score |
69
|
69
|
| Price |
$249.34
|
$51.26
|
| P/E Ratio |
70.28×
|
15.57×
|
| ROE |
-129.2%
|
36.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
71.5%
|
96.5%
|
| Debt / Equity |
-11.93×
|
0.09×
|
| Dividend Yield |
2.7%
|
0.0%
|
| RSI (14) |
48.9
|
33.7
|
| Beta |
0.28
|
0.422
|
| Expected Upside |
—
|
+12.3%
|
AI Committee View
Current Innellis committee reasoning for ABBV versus EXEL.
The committee scores are tied.
ABBV and EXEL both score 69/100.
ABBV Committee View
75% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.20 across 84 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
EXEL Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical